Skip to main content
. 2020 Oct 8;61:103054. doi: 10.1016/j.ebiom.2020.103054

Table 1.

The distributions of demographic and clinicopathologic characteristics of colorectal cancer patients in the two cohorts.

Discovery cohort Validation cohort
(158/499)* (72/315)* P
Age <0.001
 ≤ 60 year 195 (39.1%) 180 (57.1%)
 > 60 year 304 (60.9%) 135 (42.9%)
Sex 0.914
 Male 301 (60.3%) 188 (59.7%)
 Female 198 (39.7%) 127 (40.3%)
T-stage <0.001
 T1 14 (2.8%) 0 (0%)
 T2 76 (15.2%) 0 (0%)
 T3 360 (72.1%) 261 (82.9%)
 T4 49 (9.8%) 54 (17.1%)
N-stage 0.039
 N0 264 (52.9%) 141 (44.8%)
 N1 145 (29.1%) 117 (37.1%)
 N2 90 (18.0%) 57 (18.1%)
Stage <0.001
 I 71 (14.2%) 0 (0%)
 II 191 (38.3%) 142 (45.1%)
 III 228 (45.7%) 173 (54.9%)
 IV 9 (1.8%) 0 (0%)
Tumour site 0.147
 Colon 287 (57.5%) 164 (52.1%)
 Rectum 212 (42.5%) 151 (47.9%)
Median follow-up time (95% CI) 89 (79-96) 51 (50-53)
1-year survival rate (95% CI) 93.2% (91.0%-95.4%) 96.8% (94.9%-98.8%) 0.038
3-year survival rate (95% CI) 80.0% (76.5%-83.6%) 83.5% (79.5%-87.7%) 0.243
5-year survival rate (95% CI) 74.3% (70.6%-78.3%) 72.5% (66.1%-79.5%) 0.590

Note: P value was performed by Kruskal–Wallis or χ2 test where appropriate.

Numbers in parentheses are number of events/total number of patients.

Abbreviation: CI, confidence interval.